Xplora reported strong demand for its products and subscriptions in the Q3 report, and it reported g...
Redeye comments on Polygiene's CEO shift that was announced today.
* NetApp +5% on EPS beat, but reiterated low growth revenue guidance * Dell +3%, storage revenues de...
Redeye comments on Iconovo’s announcement of a directed share issue and a fully guaranteed rights is...
Redeye notes that Xplora’s third-quarter report marks a distinct inflection in profitability, with a...
Redeye provides an updated valuation of Alligator as the subscription price in the rights issue, SEK...
Xplora's gross profit came in stronger than expected at NOK 263m, 4% higher than consensus, driven b...
Redeye comments on Surgical Science dropping an absolute bomb of a press release.
Redeye initiates coverage of Ferroamp, a greentech company offering a modular hardware and software ...
* ~SEK 26m defence order announced earlier today * Backlog of ~SEK 390m * Provides additional visibi...
Redeye comments on Faron’s decision to trigger the second €10m tranche of the Heights Capital Manage...
We have updated our investment view on Mendus following its expanded strategy for vididencel to chro...
Redeye comments on CMS’s finalised reimbursement rates, effective from January 2026.
Today, I-Tech announced a strategic partnership (MoU) together with Chinese Havey, to develop and co...
Flowscape levererar ännu ett kvartal med ett positivt rörelseresultat och en stärkt rörelsemarginal ...
Redeye endorses today’s news that Sprint Bioscience has sold its TREX1 program to Gilead Sciences, i...
* Q3: +24% sales growth, 1.3% adj. EBIT margin * '25e-'27e adj.
Prospekterings- och gruvutvecklingsbolaget Bluelake Mineral har påbörjat arbetet med en PFS (Pre-Fea...
Redeye provides a research update following the Q3 report recently published by Initiator Pharma.
Flexion’s latest quarterly update marks a period of transition, with financial performance slightly ...
